Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$15.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Factual Report
$138.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CryoLife Inc Receives CE Mark For HeRo Graft


Monday, 10 Jun 2013 08:34am EDT 

CryoLife, Inc. announced that achievement of a CE (Conformite Europeenne) Mark for the HeRO (Hemodialysis Reliable Outflow) Graft system produced at the Company's new manufacturing facility in Atlanta. The HeRO Graft is a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous stenosis. 

Company Quote

9.85
-0.15 -1.50%
23 Apr 2014